Terapia ablativa con yodo-131: juicio crítico de la evidencia. ¿Tiempo de cambiar paradigmas?


  1. Schlumberger M, Catargi B, Borget I, et al. Strategies in radioiodine ablation in patients with low-risk thyroid cancer. N Eng J Med 2012;366:1663-73.
  2. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Eng J Med 2012;366:1674-85.
  3. Alexander EK, Larsen PR. Radioiodine for thyroid cancer - Is less more? (Editorial). N Eng J Med 2012;366:1732-3.
  4. Sawka A, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: A systematic review and meta-analysis. Thyroid 2009;19:451-7.
  5. Iyer NG, Morris L, Tuttle M, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 2011;117:4439-46.
  6. Kukulska A, Krajewska J, Gawkowska-Suwińska M, et al. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Research 2010;3:9
  7. Schvartz C, Bonnetain F, Dabakuyo S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab 2012;97:1526-35.
  8. Mazzaferri E, Jhiang S. Long-term impact of initial surgical and medical therapy on papillaty and follicular thyroid cancer. Am J Med 1994;97:418-28.
  9. Hay I, Thompson G, Grant C, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940 –1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26: 879-85.
  10. Sawka A, Brierley J, Tsang R, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin N Am 2008;37:457-80.
  11. Radioiodine ablation in low-risk thyroid cancer (Correspondence). N Eng J Med 2012;367:672-5.
  12. Bal C, Kumar A and Pant G. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: A randomized clinical trial in 509 patients. J Clin Endocrinol Metab 2004;89:1666-73.
  13. Bal C, Padhy A, Jana S, et al. Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996;77:74-80.